Jérôme Fayette

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text

Medicine, Oncology, Metastasis +5

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Leora Horn, David R. Spigel, Everett E. Vokes et al. · Journal of Clinical Oncology · 2017 · 875 citations · Full text

Medicine, Oncology, Pharmacology +16

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · Oral Oncology · 2018 · 800 citations · Full text

Medicine, Oncology, Metastasis +14

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Esma Saâda-Bouzid, Cécile Defaucheux, Andy Karabajakian et al. · Annals of Oncology · 2017 · 609 citations

Medicine, Oncology, Pharmacotherapy +16